کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5523911 1401397 2016 12 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Current therapy guidelines for Waldenstrom's macroglobulinaemia
ترجمه فارسی عنوان
دستورالعمل های درمانی فعلی برای ماگرولووبولینمی والدنستروم
کلمات کلیدی
ریتوکسیماب، ایبوتینیب، بورتزومیب، کارفیلزیمیب، فلوودارابین،
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی

Waldenstrom's macroglobulinaemia (WM) is a B-cell neoplasm in which bone marrow is infiltrated by lymphoplasmacytic cells that secrete monoclonal immunoglobulin M (IgM). More than a decade ago, specific criteria were agreed to define diagnosis and symptomatic disease requiring therapy; however, treatment recommendations change as new options emerge. Treatment decisions consider specific disease characteristics (burden of disease, IgM levels, presence of cytopenias) and patient characteristics (age, comorbidities, toxicity). Recently, the impact of specific mutations (in MYD88 and CXCR4) in response to specific therapies has been reported, and this may affect treatment decisions in the future. Chemo-immunotherapy combinations based on rituximab with cyclophosphamide/dexamethasone, bendamustine or bortezomib/dexamethasone are indicated for most patients. The BTK inhibitor ibrutinib was recently approved for patients with WM, and is a new option for selected newly diagnosed or relapsing patients. New B-cell receptor inhibitors, second-generation proteasome inhibitors and mammalian target of rapamycin inhibitors are promising; however, more data are needed from high-quality clinical trials.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Best Practice & Research Clinical Haematology - Volume 29, Issue 2, June 2016, Pages 194-205
نویسندگان
, ,